ACA5. Decision making in dementia

Lead Research Organisation: University of Cambridge

Abstract

How do you decide what to do, what action to take? Many patients with brain damage, Parkinson’s disease or dementia have difficulty making every day decisions about what to do, in the right place or at the right time. Patients may also have difficulty with mental flexibility, required to do different things when circumstances change, or to stop oneself when needed.
Our research group uses brain scanning and new methods in computer science and psychology to understand how healthy people and those with brain illnesses make decisions about what to do, and what not to do.
These decisions are made possible by the flow of information through brain networks. We use MRI and MEG type brain scanners to study these networks, in health, over the lifespan, and in people with emerging dementia.

Technical Summary

Advances in new treatments for dementia require a new mechanistic understanding of disease, linking changes in cognitive function to underlying neural systems and their pharmacology. They also require new tools to identify the signatures of nascent pathology in (as yet) asymptomatic patients that can be used to safely and reliably track the emergence of disease in the context of preventive and therapeutic clinical trials.
In the first part of this program, we develop new models of cognitive function, based neurophysiological models of decision making circuits. We examine decisions about behavioural control (including response inhibition), volition and the perception of environmental cues that guide actions. Using accumulation-to-threshold models of perception and behaviour, we will determine the processes by which sensory inputs are transformed to motor outputs, and the vulnerability of these processes to two different disorders: Parkinson’s disease and Alzheimer’s disease.
In the second part of the program, we will examine the problem that some people have increasingly poor cognitive function with age. This may be the presence of subclinical dementias, and we will compare neural signatures in healthy older adults to those with early dementia. However, unsuccessful cognitive ageing is not necessarily just a matter of early dementia.
Even those without emerging dementia will vary in their cognitive ageing profile, for reasons that we will elucidate. This builds on the CamCAN study of healthy ageing, bringing in for the first time those adults who performed poorly on screening tests. We will apply a tailored battery of imaging and psychological assessments, using MRI, fMRI and MEG, and use supervised machine earning methods to identify the neural factors that are associated with poor function. These will be compared with neural factors associated with early AD.
This program links directly to the Cambridge Centre for Ageing and Neuroscience (CamCAN) and the Dementias Platform UK, both in terms of the Synaptic Health Theme for Experimental Medicines, and the Deep and Frequent Phenotyping study of prodromal dementia. The MRC “ACA5. Decision making in dementia” provides vital links between normative studies, ageing and neurodegeneration. Through my Wellcome Trust Senior Research Fellowship and the NIHR Biomedical Research Centre’s Neurodegeneration and dementia theme we are developing pharmacological interventions to restore cognition, with direct translation from ACA5 innovations to clinical populations.

Publications

10 25 50
publication icon
Adams NE (2020) GABA-ergic Dynamics in Human Frontotemporal Networks Confirmed by Pharmaco-Magnetoencephalography. in The Journal of neuroscience : the official journal of the Society for Neuroscience

publication icon
Bauermeister S (2020) The Dementias Platform UK (DPUK) Data Portal. in European journal of epidemiology

publication icon
Bevan-Jones RW (2018) [18F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion. in Annals of clinical and translational neurology

publication icon
Bevan-Jones WR (2019) In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. in Annals of clinical and translational neurology

 
Title MEG & ME 
Description With ISSF funding, out team held a series of public open evenings to discuss research of interest to the public, to define a sho set of questions and design the experiments to answer them, and then carry it out using MEG. The project was filmed, and presented at a final public discussion meeting at the Cambridge Science Festival 
Type Of Art Film/Video/Animation 
Year Produced 2015 
Impact The project clearly caught he public's imagination, and over 100 members of the public took part across the weeks. https://vimeo.com/116423919 presents a final summary video 
URL https://vimeo.com/116423919
 
Title Misplaced in Space (September 2017) 
Description A collaboration with University of East Anglia, to portray the impact of Dementia 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2017 
Impact A film of the exhibition is available; 
URL https://vimeo.com/229381641
 
Description AI-MIND Consortium SAB
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
Impact The AI-MIND Consortium is to delivery new artificial intelligence methods to improve diagnosis and prognosis in dementia
URL https://accelopment.com/projects/ai-mind/
 
Description Cambridge Dementia Course
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
URL http://www.cambridgedementiacourse.com/index.html
 
Description Cambridge Dementia Course
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact a series of talks on Dementia diagnosis, management and healthcare integration
 
Description Cambridge Dementia Course
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact A series of talks delivered at the nationally renowned CDC on dementia, diagnostics and management
 
Description DPUK2Associate Director
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact DPUK is leading academic-industrial partnerships for dementia research, and coordinating the 'ecosystem' for dementia research and care in the UK. As associate Director and lead for Experimental Medicine, my role is to accelerate early phase clinical trials though partnerships with industry, academic and third-sector stakeholder collaborations
URL https://www.dementiasplatform.uk/
 
Description Memory Assessment Services
Geographic Reach National 
Policy Influence Type Participation in a national consultation
Impact A discussion and proposal on adaptation of Memory Services to COVID, and the adoption of Telemedicine, with safety, equality of access, and forward planning for post COVID
URL http://www.yhscn.nhs.uk/media/PDFs/mhdn/Dementia/Covid%2019/MAS/MSA%20-%20A%20New%20Way%20of%20Worki...
 
Description NIHT Translational Research Collaboration for dementia
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact To facilitate multilateral research across academic, healthcare and industrial partners in the UK, for better and faster dementia research. Reports to NIHR Office for Clinical Research Infrastructure (NOCRI)
URL https://www.nihr.ac.uk/partners-and-industry/industry/collaborate-with-us/dementia.htm
 
Description Prof J B Rowe: meeting Challenge on Dementia 2020 (24th May 19)
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Rowe - Masterclass (23rd March 2018). Danish Dementia Research Centre, Copenhagen, Denmark
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Masterclass in front of practitioners. Ad hoc patient review as training.
 
Description Trond Mohn Foundation
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
Impact Advisory committee for a major biomedical research foundation
 
Description "Dementias Platform UK" Co-applicant with principal applicant John Gallacher (Oxford) and co-applicants Ronan Lyons, James Rowe, Carol Routledge, Declan Jones
Amount £7,500,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2021 
End 12/2025
 
Description "Synaptic Health In Neurodegeneration" PI Prof James B Rowe Co-applicants Kia Nobre and Mark Woolrich
Amount £400,000 (GBP)
Organisation MRC Dementias Platform UK 
Sector Academic/University
Country United Kingdom
Start 10/2021 
End 09/2024
 
Description (Deborah Oakley PhD stipend) The Links Between Cardiovascular Health and Age-Related Declines in Brain Structure, Function and Cognition
Amount £50,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2019 
End 09/2023
 
Description (Xulin Liu PhD stipend) Integration of neuronal and vascular effects in neurodegenerative transdiagnostics (INVENT)
Amount £50,000 (GBP)
Organisation Chinese Scholarship Council 
Sector Charity/Non Profit
Country China
Start 10/2020 
End 09/2023
 
Description A new noradrenergic strategy for treatment of PSP
Amount £653,896 (GBP)
Funding ID MR/P01271X/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2020
 
Description A standardized, multilingual, mini linguistic state examination (MLSE) for classifying and monitoring primary progressive aphasia.
Amount £358,924 (GBP)
Funding ID RG82683 
Organisation St George's University 
Sector Academic/University
Country Grenada
Start 01/2017 
End 12/2019
 
Description ARUK network pilot grant
Amount £5,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 03/2019
 
Description Biomedical Research Centre Dementia Theme
Amount £118,000,000 (GBP)
Funding ID RG85367 
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2022
 
Description Bioresource
Amount £272,205 (GBP)
Funding ID RG85445 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2018
 
Description Brain Clinical Post Doctorial Fellowship to Dr Kamen Tsvetanov
Amount £192,308 (GBP)
Organisation Guarantors of Brain 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2020 
End 12/2022
 
Description Brain Network Analysis in Neurodegenerative Tauopathies
Amount £22,391 (GBP)
Funding ID RG89925 
Organisation The Evelyn Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2018 
End 12/2019
 
Description Bridging the gap: biophysical models of human frontotemporal lobar degeneration
Amount £2,025,694 (GBP)
Funding ID 220258/Z/20/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2021 
End 03/2026
 
Description Deep and Frequent Phenotyping; combinatorial biomarkers for dementia experimental medicine
Amount £6,301,078 (GBP)
Funding ID MR/N029941/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2016 
End 09/2020
 
Description Dr K Tsvetanov ARUK Travel Grant
Amount £875 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2019 
End 06/2019
 
Description Dr K Tsvetanov Cambridge Charles Slater Travel Grant 2019
Amount £1,685 (GBP)
Organisation University of Cambridge 
Department Charles Slater Fund
Sector Private
Country United Kingdom
Start 10/2019 
End 10/2019
 
Description EM7 Connectivity changes in early Alzheimer's Disease.
Amount £94,384 (GBP)
Funding ID MC_ST_CBU_2019 
Organisation MRC Doctoral Training Program 
Sector Academic/University
Country United Kingdom
Start 10/2019 
End 09/2023
 
Description EM7 NTAD: new-therapeutics-in-alzheimers-disease
Amount £1,200,000 (GBP)
Organisation MRC Dementias Platform UK 
Sector Academic/University
Country United Kingdom
Start 06/2018 
End 09/2020
 
Description EM7 UCB-J PET
Amount £370,000 (GBP)
Organisation Janssen Research & Development 
Sector Private
Country Global
Start 09/2019 
End 06/2020
 
Description Elucidating the mechanisms of psychosis in motor neuron disease - to Alicia Wilcox
Amount £108,693 (GBP)
Funding ID RG87714 
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2020
 
Description MIND-MAPS
Amount £977,920 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2017 
End 03/2020
 
Description Measuring microscopic changes at the macroscopic level in frontotemporal dementia - Fellowship to Sanne S. Kaalund
Amount kr 400,000 (DKK)
Funding ID R232-2016-2333 
Organisation Lundbeck Foundation 
Sector Charity/Non Profit
Country Denmark
Start 08/2017 
End 07/2019
 
Description Metabolic Imaging at the Cambridge 7T Terra MRI
Amount £50,000 (GBP)
Organisation Newton Fund 
Sector Public
Country United Kingdom
Start 10/2018 
End 10/2020
 
Description Multi-scale network dynamics of the ageing brain: Modelling neurocognitive function and dysfunction - Fellowship to Kamen Tsvetanov
Amount £264,375 (GBP)
Funding ID RG84427 
Organisation The British Academy 
Sector Academic/University
Country United Kingdom
Start 01/2017 
End 12/2019
 
Description New Therapeutics in Alzheimer s Disease (NTAD) - ARUK
Amount £100,000 (GBP)
Funding ID RG89702 
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 08/2020
 
Description Pilot studies in BRC portfolio - LC imaging and addiction
Amount £20,000 (GBP)
Organisation Cambridge University Hospitals NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 08/2018 
End 03/2019
 
Description Restoring noradrenergic function to improve apathy in Parkinson s disease to Claire O Callaghan
Amount £49,677 (GBP)
Funding ID RG90797 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2017 
End 07/2018
 
Description Visiting Professorship (Lundbeck Foundation, Danish Research Centre for Magnetic Resonance) - Prof James B Rowe
Amount kr 150,000 (DKK)
Organisation Lundbeck Foundation 
Sector Charity/Non Profit
Country Denmark
Start 09/2019 
End 12/2019
 
Title BIOFIND output 
Description The JPND BioIND project was led from MRC-CBU, as an international collaboration to standardize and harmonize methods for dementia research. 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2019 
Provided To Others? Yes  
Impact Data sharing across sites, the open science methods and a publication pending are outputs related to the validation and recommendations made. The research tool is part of the growing recognition of MEG's potential to transform dementia research, with novel mechanistic insights and trials outcomes, provided that industry-readiness benchmarks can be met. 
URL http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/closed-calls/brain-im...
 
Title LC atlas 
Description An atlas of locus ceruleus, currently as submisison in BioRxiv and and awaiting reviewers approval in Neuroimagine. This work is led by Dr Rong Ye. 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2020 
Provided To Others? Yes  
Impact Early and profound pathological changes are evident in the locus coeruleus (LC) in dementia and Parkinson's disease, with effects on arousal, attention, cognitive and motor control. The LC can be identified in vivo using non-invasive magnetic resonance imaging techniques which have potential as biomarkers for detecting and monitoring disease progression. We created a probabilistic atlas of the LC from 53 healthy older volunteers (52-84 years) using a sensitive magnetisation transfer sequence and ultrahigh field 7T MRI to investigate the LC structure in vivo at high-resolution. We would like to make the atlas available on NITRC for researchers, for replication or to facilitate accurate LC localisation and unbiased contrast extraction in future cognitive and clinical studies. 
 
Title Sequence development and optimisation for 7T research 
Description New sequences for brain and mental health research at 7T 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2018 
Provided To Others? Yes  
Impact Many studies are underway, but these have yet to be published, or to have reached health policy. Our progress has contributed to the national MR debate on higher field imaging in the UK, including nascent proposals for 14T imaging as a national research unit 
URL https://www.wbic.cam.ac.uk/facilities/7t-terra
 
Title iElectrodes toolbox: for invasive electroencephalography (EEG) recordings 
Description The localization of intracranial electrodes is a fundamental step in the analysis of invasive electroencephalography (EEG) recordings in research and clinical practice. The conclusions reached from the analysis of these recordings rely on the accuracy of electrode localization in relationship to brain anatomy. However, currently available techniques for localizing electrodes from magnetic resonance (MR) and/or computerized tomography (CT) images are time consuming and/or limited to particular electrode types or shapes. We present iElectrodes, an open-source toolbox that provides robust and accurate semi-automatic localization of both subdural grids and depth electrodes. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2017 
Provided To Others? Yes  
Impact The software project is made available to the scientific community in the form of an open-source MATLAB® toolbox that can be freely downloaded from https://sourceforge.net/projects/ielectrodes/ for research porpoises only under GNU General Public License. 
URL https://sourceforge.net/projects/ielectrodes/
 
Description BioFIND - JPND 
Organisation EU Joint Programme - Neurodegenerative Disease Research (JPND)
Country European Union (EU) 
Sector Public 
PI Contribution We led the JPND award on the use of MEG in harmonisation and standarisation for Dementia research, bringing together Pharma and Academic partners from ten sites.
Collaborator Contribution Expertise, knowledge sharing, and scoping of future project needs.
Impact A project initiation report is submitted. A new data sharing project has begun across six sites.
Start Year 2016
 
Description CLEAR-Huntington's Disease 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of MEG-related methods and analysis advice (postdocs involved: Dr Laura Hughes and Dr Ece Kocagoncu).
Collaborator Contribution N/A
Impact Cambridge and UCL collaboration only.
Start Year 2019
 
Description Cam-CAN 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Design and analysis of response control and inhibition studies, for fMRI and MEG. Started a new arm in 2015 called the Cam-CAN Frail study.
Collaborator Contribution A strong collaboration for epidemiologically validated ageing research, across multiple modalities.
Impact doi: 10.1186/s12883-014-0204-1; doi: 10.1038/ncomms6658; doi: 10.1002/hbm.22768; doi: 10.1016/j.neurobiolaging.2015.07.028; doi: 10.3390/ijerph121215003; doi: 10.1523/JNEUROSCI.2733-15.2016; doi: 10.1016/j.cortex.2016.05.001; doi: 10.1038/srep32527; doi: 10.1038/ncomms13034; doi: 10.1038/ncomms14743; doi: 10.1038/ncomms15671; more publications to come;
Start Year 2010
 
Description Cambridge LMU strategic partnership 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Country Germany 
Sector Academic/University 
PI Contribution A new strategic partnership to build a common research framework on cognitive reserve, resilience and dementia Bilateral meetings, joint grant writing, and visiting professorships
Collaborator Contribution A new strategic partnership to build a common research framework on cognitive reserve, resilience and dementia Bilateral meetings, joint grant writing, and visiting professorships
Impact Internal reports and new grant proposals
Start Year 2019
 
Description Claire O Callaghan - Restoring noradrenergic function to improve apathy in Parkinson s disease 
Organisation University of Cambridge
Department Department of Psychiatry
Country United Kingdom 
Sector Academic/University 
PI Contribution Input on study design
Collaborator Contribution Study design, will do data collection and analyses, publications pending
Impact publications still pending
Start Year 2017
 
Description ENIGMA MEG working group 
Organisation University of Southern California
Country United States 
Sector Academic/University 
PI Contribution Supply of a dementia and healthy participants dataset.
Collaborator Contribution TBC
Impact A new collaboration in development, initiated late 2020 and the first meeting took place in January 2021.
Start Year 2021
 
Description JPND EUFIND - European Ultrahigh Field Imaging Biomarkers for Dementia 
Organisation EU Joint Programme - Neurodegenerative Disease Research (JPND)
Country European Union (EU) 
Sector Public 
PI Contribution An international consortium for harmonisation and standardisation of UHF-MRI for Dementia Research. We have contributed expertise, data, and engaged in a pilot study for feasibility and methods development
Collaborator Contribution An international consortium for harmonisation and standardisation of UHF-MRI for Dementia Research. Our partners from 20 EU sites have contributed expertise, data, and engaged in a pilot study for feasibility and methods development
Impact A project initiation report is submitted to JPND
Start Year 2016
 
Description LC collaboration 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution We have engaged with two UCL groups who have a shared interest in noradrenergic systems, and imaging f the locus ceruleus in particular, with data sharing and plans for joint papers.
Collaborator Contribution New sequences and clinical applications of the MR technology
Impact A joint position paper Data sharing
Start Year 2018
 
Description MEG-UK Partnership 
Organisation Medical Research Council (MRC)
Department MRC Cognition and Brain Sciences Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution The partnership consists of Aston, Cambridge Cognition and brain Sciences Unit, Cardiff, Glasgow, Nottingham, Oxford, University College London, and York. As well as supporting a cohort of doctoral students, providing a unified training courses, and developing standardised data acquisition and analysis pipelines, one of the key research goals is to establish a normative database using common protocols across sites. Each of the collaborating sites will scan 80 individuals to yield a total of 640 datasets, primarily comprised of healthy volunteers. The ability to make valid comparisons with clinical populations requires characterisation of inter-individual variability in a healthy cohort using the same protocols and analysis pipelines. The standardised protocols will involve a range of validated tasks involving sensory, cognitive, and motor tasks, as well as resting-state recordings. The project will address critical aims of the partnership in terms of research integration, and will engender development of a principled approach to cross-site collaboration whereby it is possible to pool data from different scanner platforms, assess the reliability of measures and develop common analysis pipelines. The process will also establish standards for future cross-site collaborations to ensure data is collected and curated appropriately to enable data sharing and linking with other imaging modalities.
Collaborator Contribution Principal investigators include: Krish Singh (Cardiff, lead applicant), Paul Furlong (Aston), Ian Holliday (Aston), Klaus Kessler (Aston), Richard Henson (Cambridge), Yuri Shytrov (Cambridge), Khalid Hamandi (Cardiff), Joachim Gross (Glasgow), Peter Ulhaas (Glasgow), Peter Morris (Nottingham), Matthew Brookes (Nottingham), Gareth Barnes (UCL), Vladimir Litvak (UCL), Gary Green (York),
Impact TBC
Start Year 2018
 
Description MINDMAPS AD UK 
Organisation MRC Dementias Platform UK
Country United Kingdom 
Sector Academic/University 
PI Contribution We are collaborating with Imperial on the Mindmaps project, to combine their UCBJ PET data with our MEG data. The aim is to test the link between synaptic density changes and resting state connectivity in Alzheimer's disease.
Collaborator Contribution Dr Eugenii Rabiner of Invicro, leads MIND MAPS - a collaboration between Invicro, the world's leading neuroscience translational imaging centre, six industry partners (AbbVie, Biogen, Celgene, Hamamatsu Photonics, Pfizer and Takeda) and UK's leading academic centres (King's College, Imperial College, University College, Cambridge, Newcastle). Each partner has contributed their particular expert knowledge. Invicro provided the overall scientific design and cutting edge imaging methodologies, the academic partners contribute disease specific knowledge and expertise in patient selection and care. Industry partners provide the knowledge of promising treatment targets and treatments. The collaboration combines these ingredients to ensure that the techniques being developed and tested by the team are truly fit for purpose to support future disease modifying clinical trials. It demonstrates a collaborative way of working that signposts the future of dementia research.
Impact TBC
Start Year 2017
 
Description NIHR BRC 
Organisation National Institute for Health Research
Department NIHR Cambridge Biomedical Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Biomarker development, including cognitive and imaging based deep phenotyping;
Collaborator Contribution Cellular, physiological, radio-chemistry, genetic and pharmaceutical innovations within a pipeline for novel drug discovery;
Impact Adams, N. E., Hughes, L. E., Phillips, H. N., Shaw, A. D., Murley, A. G., Nesbit, D., Cope, T. E., Bevan-Jones, W. R., Passamonti, L., Rowe, J. B. (2020). GABA-ergic dynamics in human frontotemporal networks confirmed by pharmaco magnetoencephalography, Journal of Neuroscience, https://doi.org/10.1523/JNEUROSCI.1689-19.2019. Lewis-Smith, D. J., Wolpe, N., Ghosh, B. C. P., Rowe, J. B. (2020). Alien limb in the corticobasal syndrome: phenomenological characteristics and relationship to apraxia, Journal of Neurology, https://doi.org/10.1007/s00415-019-09672-8. Jabbari, E., Chelban, V., Holland, N., Jones, P. S., Lamb, R., Rawlinson, C., Guo, T., Costantini, A. A., Tan, M. M. X., Heslegrave, A. J., Roncaroli, F., Klein, j. C., Ansorge, O., Allinson, K. S. J., Jaunmuktane, Z., Holton, J. L., Revesz, T., Warner, T. T., Lees, A. J., Zetterberg, H., Russell, L. L., Bocchetta, M., Rohrer, J. D., Williams, N. M., Grosset, D. G., Burn, D. J., Pavese, N., Gerhard, A., Kobylecki, C., Leigh, P. G., Church, A., Hu, M. T. M., Woodside, J., Houlden, H., Rowe, J. B., Morris, H. R. (2020). Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome, JAMA Neurology, doi:10.1001/jamaneurol.2019.4347. van der Ende, E. L,, Meeter, L. H., Poos, J. M., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., Papma, J. M., de Jong, F. J., Verberk, I., Teunissen, C. E., Rizopoulos, D., Heller, C., Convery, R. S., Moore, K. M., Bocchetta, M., Neason, M., Cash, D. M., Borroni, B., Galimberti, D., Sanchez-Valle, R., Laforce, Jr R., Moreno, F., Synofzik, M., Graff, C., Masellis, M., Tartaglia, M. C., Rowe, J. B., Vandenberghe, R., Finger, E., Tagliavini, F., de Mendonça, A., Santana, I., Butler, C., Ducharme, S., Gerhard, A., Danek, A., Levin, J., Otto, M., Frisoni, G. B., Cappa, S., Pijnenburg, Y. A. L., on behalf of the GENetic Frontotemporal Dementia Initiative (GENFI), Rohrer, J. D., van Swieten, J. C. (2019). Longitudinal serum neurofilament light chain in genetic frontotemporal dementia: a multicentre cohort study. Lancet Neurology, 18: 1103-1111, https://doi.org/10.1016/S1474-4422(19)30354-0. Shafto, M. A., Henson, R. N., Matthews, F. E., Taylor, J. R., Emery, T., Erzinclioglu, S., Hanley, C., Rowe, J. B., Cusack, R., Calder, A. J., Marslen-Wilson, W. D., Duncan, J., Dalgleish, T., Brayne, C., Cam-CAN, Tyler, L. K. (2019). Cognitive Diversity in a Healthy Aging Cohort: Cross-Domain Cognition in the Cam-CAN Project, Journal of Aging and Health, doi: 10.1177/0898264319878095 [ahead of print], PMID: 31592706 Lansdall, C. J., Coyle-Gilchrist, I. T. S., Vázquez Rodríguez, P., Wilcox, A., Wehmann, E., Robbins, T. W., Rowe, J. B. (2019). Prognostic importance of apathy in syndromes associated with Frontotemporal lobar Degeneration, Neurology, 92(14):e1547-e1557. doi: 10.1212/WNL.0000000000007249, PMID: 30842292, PMC: 6448451. Borchert, B. J., Rittman, T., Rae, C. L., Passamonti, L., Jones, P. S., Vatansever, D., Vazquez-Rodriguez, P., Ye, Z., Nombela, C., Hughes, L. E., Robbins, T. W., Rowe, J. B. (2019). Atomoxetine and citalopram alter brain network organization in Parkinson's disease, Brain Communications, 1:1 fcz013, https://doi.org/10.1093/braincomms/fcz013. PMID: [pending], PMC: [pending]. Nicastro, N., Surendranathan, A., Mak, E., Rowe, J. B.*, O'Brien, J. T.* (2019). 11C-PK11195 PET imaging and white matter changes in Parkinson's disease dementia, Annals of Clinical and Translational Neurology, doi: 10.1002/acn3.50877, PMID: 31507085, PMC: [pending]. Low, A., Mak, E., Malpetti, M., Chouliaras, L., Nicastro, N., Su, L., Holland, N., Rittman, T., Vázquez Rodríguez, P., Passamonti, L., Bevan-Jones, W. R., Jones, P. S., Rowe, J. B.*, O'Brien, J. T.* (2019). Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloid-positive mild cognitive impairment is associated with key clinical features, Alzheimer's & Dementia: Diagnosis, Assessment, & Disease Monitoring, 11: 690-699, DOI: https://doi.org/10.1016/j.dadm.2019.08.001, PMID: 31667328, PMC: 6811895. Tavares, T. P., Mitchell, D. G. V., Coleman, K., Shoesmith, C., Bartha, R., Cash, D. M., Moore, K. M., van Swieten, J. C., Borroni, B., Galimberti, D., Tartaglia, M. C., Rowe, J. B., Graff, C., Tagliavini, F., Frisoni, G., Cappa, S., Laforce, R. Jr, de Mendonça, A., Sorbi, S., Wallstrom, G., Masellis, M., Rohrer, J. D., Finger, E. C., GENetic Frontotemporal Dementia Initiative (GENFI) (2019). Ventricular volume expansion in presymptomatic genetic frontotemporal dementia, Neurology, doi: 10.1212/WNL.0000000000008386, PMID: 31578297, PMC: [pending]. Passamonti, L., Tsvetanov, K. A., Jones, P. S., Bevan-Jones, W. R., Arnold, R., Borchert, R. J., Mak, E., Su, L., O'Brien, J. T.*, Rowe, J. B.* (2019). Neuroinflammation and functional connectivity in Alzheimer's disease: interactive influences on cognitive performance, Journal of Neuroscience, doi: 10.1523/JNEUROSCI.2574-18.2019. PMID: 31320450, PMC: 6733539. Jabbari, E., Woodside, J., Guo, T., Magdalinou, N. K., Chelban, V., Athauda, D., Lees, A. J., Foltynie, T., Houlden, H., Church, A., Hu, M. T., Rowe, J. B., Zetterberg, H., Morris, H. R. (2019). Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes, Journal of Neurology, Neurosurgery and Psychiatry, 90(7):768-773. doi: 10.1136/jnnp-2018-320151. PMID: 30867224, PMC: 6585258. Hughes, L. E., Henson, R. N., Pereda, E., Bruña, R., López-Sanz, D., Quinn, A. J., Woolrich, M. W., Nobre, A. C., Rowe, J. B., Maestú, F., BioFIND Working Group (2019). Biomagnetic biomarkers for dementia: A pilot multicentre study with a recommended methodological framework for magnetoencephalography, Alzheimers & Dementia (Amsterdam, Netherlands), 11:450-462. doi: 10.1016/j.dadm.2019.04.009. PMID: 31431918, PMC: 6579903. Shaw, A. D., Hughes, L. E., Moran, R., Coyle-Gilchrist, I., Rittman, T., Rowe, J. B. (2019). In Vivo Assay of Cortical Microcircuitry in Frontotemporal Dementia: A Platform for Experimental Medicine Studies. Cerebral Cortex. 2019. doi: 10.1093/cercor/bhz024. PMID: 31216360. van Eimeren, T., Antonini, A., Berg, D., Bohnen, N., Ceravolo, R., Drzezga, A., Höglinger, G. U., Higuchi, M., Lehericy, S., Lewis, S., Monchi, O., Nestor, P., Ondrus, M., Pavese, N., Peralta, M.C., Piccini, P., Pineda-Pardo, J. Á., Rektorová, I., Rodríguez-Oroz, M., Rominger, A., Seppi, K., Stoessl, A. J., Tessitore, A., Thobois, S., Kaasinen, V., Wenning, G., Siebner, H. R., Strafella, A. P., Rowe, J. B. (2019). Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers & Dementia (Amsterdam, Netherlands). 11:301-309. doi: 10.1016/j.dadm.2019.01.011. PMID: 30984816, PMC: 6446052. Rittman, T., Borchert, R., Jones, P. S., van Swieten, J., Borroni, B., Galimberti, D., Masellis, M., Tartaglia, M. C., Graff, C., Tagliavini, F., Frisoni, G. B., Laforce, R. Jr, Finger, E., Mendonça, A., Sorbi, S., Rohrer, J. D., Rowe, J. B., GENetic Frontotemporal Dementia Initiative (GENFI) (2019). Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia, Neurobioly of Aging, 77:169-177. doi: 10.1016/j.neurobiolaging.2018.12.009, PMID: 30831384; PMC: 6491498. Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T., Arnold, R., Coles, J. P., Aigbirhio, F. I., O'Brien, J. T., Rowe, J. B. (2019). In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. Annals of Clinical Translational Neurology, 6(2):373-378. doi: 10.1002/acn3.683. PMID: 30847369; PMC: 6389753.
Start Year 2017
 
Description NTAD Collaboration with UCL-UK DRI Plasma Tau Analysis 
Organisation UK Dementia Research Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution NTAD study provides blood samples obtained from participants with Alzheimer's disease.
Collaborator Contribution Collaboration with Dr Henrik Zetterberg & Dr Amanda Heslegrave, UK DRI Fluid Biomarker Laboratory at UCL, for plasma tau analysis obtained from NTAD participants.
Impact TBC
Start Year 2020
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation Alzheimer's Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation AstraZeneca
Department Astra Zeneca
Country United States 
Sector Private 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation Eli Lilly & Company Ltd
Country United Kingdom 
Sector Private 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation Johnson & Johnson
Department Janssen Pharmaceuticals
Country United States 
Sector Private 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation Oxford University Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Academic/University 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description NTAD new therapeutics in Alzheimer's disease 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution DPUK EM theme
Collaborator Contribution New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK -
Impact Annual workshop
Start Year 2017
 
Description Synaptic Health 
Organisation Alzheimer's Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation AstraZeneca
Department MedImmune
Country United Kingdom 
Sector Private 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation Eli Lilly & Company Ltd
Country United Kingdom 
Sector Private 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation Janssen Biotech, Inc.
Country United States 
Sector Private 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation MRC Dementias Platform UK
Country United Kingdom 
Sector Academic/University 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation University of Exeter
Country United Kingdom 
Sector Academic/University 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Synaptic Health 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Academic leadership and skills in new Dementia research platform; planning and applying for new funding; several meeting and phone conferences; about to initiate NTAD in Cambridge; planning of NTAD study;
Collaborator Contribution Expertise in translational neuroscience; planning; meetings; application for further funding;
Impact New Therapeutics in Dementia consortium; an interdisciplinary research group of clinicians, cognitive scientists, informatics, pharmaceutical and drug development experts; phase 0 studies for "New Therapeutics in Alzheimer's Disease" and "Deep and Frequent Phenotyping" that are designed to optimise phase II studies of disease modifying therapies and additional opportunities for insights into disease pathogenesis; data collection, analyses and publications still pending;
Start Year 2015
 
Description Testing of HPLC method in neuroscience 
Organisation University of Leipzig
Department Rudolf-Boehm-Institut für Pharmakologie und Toxikologie
Country Germany 
Sector Academic/University 
PI Contribution Determination of atomoxetine or escitalopram in human plasma by HPLC method in neuroscience - Collaboration between Dr Ralf Regenthal and Prof James Rowe to develop high-performance liquid chromatography (HPLC) method capable of monitoring escitalopram and atomoxetine in controls and patients with Parkinson's disease. The aim is create and validate a tool for drug monitoring and the study of pharmacokinetics in neuroscientific studies across the Rowe Group. Samples were sent from the Tiagabine studies of FTLD, Memantine is yet to be confirmed.
Collaborator Contribution Prof Rowe provides plasma for patients with Parkinson's disease as well subtypes Frontotemporal Lobar Degeneration. Dr Regenthal performs experiments to determine pharmacokinetic properties of those samples.
Impact https://europepmc.org/article/med/32449675
Start Year 2014
 
Description UK 7T MRI network 
Organisation Cardiff University
Department Brain Research Imaging Centre (CUBRIC)
Country United Kingdom 
Sector Academic/University 
PI Contribution establishing a new 7T imaging network, with new CRI funding and MRC Parntership grant. Updated input for 2019 - 2020 - Dr Rodgers (Cambridge Head of 7T MRI Physics) was elected coordinator of the UK7T network from 1 Nov 2019 onwards.
Collaborator Contribution establishing a new 7T imaging network, with new CRI funding
Impact A series of workshops and symposia, for training, education and research exchange. Topics include 7T-Safety, fMRI, Parallel Transmit and research updates. The project is multi-disciplinary, between clinicians in neurology, psychiatry, radiology and physicists, engineers, and data informaticians.
Start Year 2016
 
Description UK 7T MRI network 
Organisation University of Glasgow
Department Institute of Neuroscience and Psychology
Country United Kingdom 
Sector Academic/University 
PI Contribution establishing a new 7T imaging network, with new CRI funding and MRC Parntership grant. Updated input for 2019 - 2020 - Dr Rodgers (Cambridge Head of 7T MRI Physics) was elected coordinator of the UK7T network from 1 Nov 2019 onwards.
Collaborator Contribution establishing a new 7T imaging network, with new CRI funding
Impact A series of workshops and symposia, for training, education and research exchange. Topics include 7T-Safety, fMRI, Parallel Transmit and research updates. The project is multi-disciplinary, between clinicians in neurology, psychiatry, radiology and physicists, engineers, and data informaticians.
Start Year 2016
 
Description UK 7T MRI network 
Organisation University of Nottingham
Department School of Biomedical Sciences Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution establishing a new 7T imaging network, with new CRI funding and MRC Parntership grant. Updated input for 2019 - 2020 - Dr Rodgers (Cambridge Head of 7T MRI Physics) was elected coordinator of the UK7T network from 1 Nov 2019 onwards.
Collaborator Contribution establishing a new 7T imaging network, with new CRI funding
Impact A series of workshops and symposia, for training, education and research exchange. Topics include 7T-Safety, fMRI, Parallel Transmit and research updates. The project is multi-disciplinary, between clinicians in neurology, psychiatry, radiology and physicists, engineers, and data informaticians.
Start Year 2016
 
Description UK 7T MRI network 
Organisation University of Oxford
Department Oxford Centre for Functional MRI of the Brain (FMRIB)
Country United Kingdom 
Sector Academic/University 
PI Contribution establishing a new 7T imaging network, with new CRI funding and MRC Parntership grant. Updated input for 2019 - 2020 - Dr Rodgers (Cambridge Head of 7T MRI Physics) was elected coordinator of the UK7T network from 1 Nov 2019 onwards.
Collaborator Contribution establishing a new 7T imaging network, with new CRI funding
Impact A series of workshops and symposia, for training, education and research exchange. Topics include 7T-Safety, fMRI, Parallel Transmit and research updates. The project is multi-disciplinary, between clinicians in neurology, psychiatry, radiology and physicists, engineers, and data informaticians.
Start Year 2016
 
Title Tiagabine in FTLD 
Description New drug strategy for impulsivity in FTLD tested for first time. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2021
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Reduced impulsivity in selected patients. 
 
Description "Ask the Doctor" a conversation with Prof James Rowe and colleagues 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact A webinar with Q&A sessions predominantly designed for the carers of patients with FTD.
A face to face meeting was an initiation of a standalone PPI group for FTD within the Rowe Lab. By inviting patients and their carers to December '20 meeting we looked at 1) 2 research studies and reviewed them (Dr Rittman and Dr Passamonti) 2) 1 ethical question discussed within the group. Post meeting feedback was received by participants and a suggestion made for another meeting to take part later in the 2020. In addition, research nurses are sending out questionnaires to all patients/carers attending the Disorders of Movement and Cognition Clinic (DMC) and Frontotemporal Dementia Clinic (FDC) to assist us in reviewing the clinics and identifying areas of improvement and further needs.
An online zoon meeting, inviting 75 carers and their families of patients with FTD in September 2020.to a question and answer format seminar.
Year(s) Of Engagement Activity 2020
URL https://ftd.neurology.cam.ac.uk/events/FTDWEBINAR
 
Description #DementiaUncovered short film 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Alzheimer'sResearchUK sponsored this short film to describe the journey of Prof James B Rowe as a clinician and researcher.
Year(s) Of Engagement Activity 2019
URL https://vimeo.com/369752751?ref=em-share
 
Description (Cope, T. E. and) Allinson, K. (6th April 2018). Can we find a cure for dementia? Crowd Science, BBC World Service. 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Neuropathology of dementia
Year(s) Of Engagement Activity 2018
URL http://www.bbc.co.uk/programmes/w3cswvwc
 
Description (Dr Negin Holland) AD/PD conference - March 2021 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Title of Dr Holland's oral presentation: - Disease severity alters the relationship between in vivo synaptic density and tau accumulation in Progressive Supranuclear Palsy
Year(s) Of Engagement Activity 2021
URL https://cslide.ctimeetingtech.com/adpd21/attendee/confcal/persons/H
 
Description (Dr Negin Holland) ARUK Conference - March 2021 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Title of Dr Holland's poster: - In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies
Year(s) Of Engagement Activity 2020
URL https://www.alzheimersresearchuk.org/research/for-researchers/research-conference-2021/scientific-pr...
 
Description (Dr Negin Holland) Association of British Neurologist annual conference - May 2020 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Title of the poster presented by Dr Holland: Reduced synaptic density in primary tauopathies, revealed by [11C]UCB-J PET.
Year(s) Of Engagement Activity 2020
URL https://www.theabn.org/page/virtual_meeting_2020
 
Description 8th FTD UK conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact 180 delegates
10.00am Welcome to the meeting and introduction Professor Stuart Pickering-Brown, Dr Jonathan Rohrer & Professor James Rowe
10.10am The MLSE Peter Garrard (St George's Hospital London)
10.30am Functional Networks in Genetic FTD - Susceptibility and Resilience Tim Rittman (University of Cambridge)
10.50am Disease modelling approaches to FTD Alexandra Young (UCL)
11.10am Coffee break
11.40am There's something wrong with my MAM; ER-mitochondria signaling and neurodegenerative diseases Chris Miller (King's College London)
12.00pm C9orf72 FTD/ALS: mechanisms and therapeutics Adrian Isaacs (UCL)
12.20pm Gene therapy approaches to ALS Pam Shaw (Sheffield)
12.40pm Lunch
1.40pm Novel therapies for GRN-related FTD Robert Paul (Alector)
2.00pm Novel cell-based therapies for FTD Johan Lundkvist (Alzecure)
2.20pm Coffee break
2.50pm Improving the diagnostic pathway for patients with FTD Panel discussion
3.30pm Basic Science Prize for Early Career UK FTD Researcher
3.40pm Clinical Science Prize for Early Career UK FTD Researcher
3.50pm Update on UK dementia initiatives
Year(s) Of Engagement Activity 2018
URL http://www.ftduk.org/
 
Description Apathy Special Interest Group, ABN 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact An afternoon workshop for UK specialists, including lecture on work arising from this program and extensive discussion
Year(s) Of Engagement Activity 2019
 
Description Audit of Early Cognitive Disorders Clinic. April 2020 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact A face to face meeting was an initiation of a standalone PPI group for FTD within the Rowe Lab. By inviting patients and their carers to December '20 meeting we looked at 1) 2 research studies and reviewed them (Dr Rittman and Dr Passamonti) 2) 1 ethical question discussed within the group. Post meeting feedback was received by participants and a suggestion made for another meeting to take part later in the 2020. In addition, research nurses are sending out questionnaires to all patients/carers attending the Disorders of Movement and Cognition Clinic (DMC) and Frontotemporal Dementia Clinic (FDC) ( Early Cognitive disorders clinic EDC) to assist us in reviewing the clinics and identifying areas of improvement and further needs.
An audit questionnaire sent out to 75 carers and their families regarding their experience of the EDC and its related research activity to assist us in reviewing the clinics and research, identifying areas for improvement and further needs in a qualitative manner. Questions were asked about the patients happiness to be asked and take part in research, their experience, about the clinic, its access, facilities, helpfulness, if the experience was informative plus open ended questions and comments.
23 carers and one patient responded, the feedback was informative and almost overwhelmingly positive, including some personal observations. The results were subsequently fed back to the members of the group in summary form.
Year(s) Of Engagement Activity 2020
 
Description British Neuropathological Society meeting, Cirencester, UK 3-5 July 2019 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Attended by Dr Luca Passamonti and Dr Sanne Kaalund to strenghten their network in neuropathology research.
Year(s) Of Engagement Activity 2019
URL https://www.bns.org.uk/wp-content/uploads/2018/12/Programme_BNSSummerSchool2019.pdf
 
Description British Neuropsychiatry Association guest lecture - Apathy and Impulsivity in FTLD - not all dopamine, degeneration and death - Oxford 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact TBC
Year(s) Of Engagement Activity 2019
 
Description CCPP patient liaison 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact A patient liaison group, to advise and feedback on experience of research participation, and future studies' documentation.
Year(s) Of Engagement Activity 2018,2019
 
Description Cambridge Imaging Festival, Cambridge 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Dr Luca Passamonti presented a talk titled: Integrative brain imaging to understand and treat dementia.
Year(s) Of Engagement Activity 2019
URL https://radiology.medschl.cam.ac.uk/wp-content/uploads/2019/05/CIF-Programme-with-link.pdf
 
Description Cambridge Science Festival March 2021 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact 4:00pm-5:30pm on Wednesday 31 March

The role of a memory clinic is multi-faceted and can offer vital support to those affected by various forms of dementia. The Cambridge Memory Clinic provides assessment and management for a wide range of memory and cognitive disorders, for example, due to neurodegeneration (Alzheimer's disease, Mild Cognitive Impairment, Frontotemporal dementia, Dementia with Lewy Bodies) and more.

Join our team for a discussion about memory clinics in the context of dementia. How they can help, and what to expect - including their role in leading research that matters to patient care. Short presentations followed by a live Q&A session with consultant neurologists. During the session, the audience can submit their questions through a monitored Q&A chat box.

Speakers:

- Professor James Rowe

- Dr Timothy Rittman

- Dr Andrew Graham
Year(s) Of Engagement Activity 2021
URL https://www.festival.cam.ac.uk/events/my-memory-clinic-and-me
 
Description Care pathways for CBD 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Working group to develop new care pathways and national standards of care for CBD and related disorders
Year(s) Of Engagement Activity 2018
 
Description Channel 4 - cognitive enhancement 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Interviews and experiment conducted under on camera, into cognitive enhancement
Year(s) Of Engagement Activity 2018
 
Description Cope, T. E. (3rd April 2018). Senses Month. Can you hear me? Podcast, The Naked Scientist. 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact https://www.thenakedscientists.com/podcasts/naked-scientists-podcast/senses-month-can-you-hear-me.
Year(s) Of Engagement Activity 2018
URL http://www.thenakedscientists.com/podcasts/naked-scientists-podcast/senses-month-can-you-hear-me
 
Description Cope/Rowe - Alzheimer's breakthrough? Scientists show how toxic protein rips through the brain (2018). 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Article on Cope et al., Brain. By Giles Sheldrick. Express - online. www.express.co.uk/life-style/health/900212/Alzheimer-s-disease-toxic-protein-rips-through-brain-scientists-reveal
Year(s) Of Engagement Activity 2018
URL http://www.express.co.uk/life-style/health/900212/Alzheimer-s-disease-toxic-protein-rips-through-bra...
 
Description Cope/Rowe - Alzheimer's protein may spread like an infection, human brain scans suggest (2018). 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Article on Cope et al., 2018 in Brain. By Meredith Wadman. Science Magazine www.sciencemag.org
http://www.sciencemag.org/news/2018/01/alzheimer-s-protein-may-spread-infection-human-brain-scans-suggest
Year(s) Of Engagement Activity 2018
URL http://www.sciencemag.org/news/2018/01/alzheimer-s-protein-may-spread-infection-human-brain-scans-su...
 
Description Cope/Rowe - How Alzheimer's disease spreads throughout the brain - new study. The Conversation (2018). 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Media article on Cope et al., Brain in "The Conversation".
Year(s) Of Engagement Activity 2018
URL http://theconversation.com/how-alzheimers-disease-spreads-throughout-the-brain-new-study-89692
 
Description Cope/Rowe - Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread may prevent the disease from taking hold (2018). 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Press release by the Cambridge University regarding new article published by Cope et al., in Brain.
Year(s) Of Engagement Activity 2018
 
Description Danish Dementia masterclass 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A whole day masterclass in Copenhagen for dementia specialists across Scandinavia.
I lecture, then the rest of the day in case based discussions, analysis and Q&A.
Year(s) Of Engagement Activity 2018
 
Description Dementia care videos 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact A series of recorded interviews with local 6th form students, preparing either video or written documentary work on dementia care, research and progress
Year(s) Of Engagement Activity 2019
 
Description Diagnosis and management of PSP 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact SW Movement disroders group, event at Royal College of Physicians
Year(s) Of Engagement Activity 2018
 
Description Dr A Tomassini University of East Anglia: Dementia Datathon organised by Dementia Platform UK (6-8 Nov '19) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact 6-8/11/19 - University of East Anglia: Dementia Datathon organised by Dementia Platform UK. https://www.uea.ac.uk/about/-/uk-s-brightest-young-minds-meet-to-unlock-dementia
Year(s) Of Engagement Activity 2019
 
Description Dr A Tomassini poster: International Symposium on Motivational And Cognitive Control, Berlin, (16-18th Aug '19) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 16-18/09/19- Berlin: International Symposium on Motivational And Cognitive Control (poster). http://www.mcc2019.com/
Year(s) Of Engagement Activity 2019
 
Description Dr A Tomassini talk: Postdoc Neuroscience Network Symposium, Cambridge (27th Jul '19) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact 27/07/19 - Cambridge: Postdoc Neuroscience Network Symposium (talk). https://www.eventbrite.co.uk/e/postdoc-neuroscience-network-symposium-2019-tickets-60542729935
Year(s) Of Engagement Activity 2019
 
Description Dr A Tomassini, Workshop on predictive processing in the brain, London (28th Feb '19) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact 28/02/2019 - London: Workshop on predictive processing in the brain. https://www.eventbrite.co.uk/e/swc-workshop-predictive-processing-in-the-brain-tickets-53811287008?utm-medium=discovery&utm-campaign=social&utm-content=attendeeshare?f=estw&utm-source=tw&utm-term=listing
Year(s) Of Engagement Activity 2019
 
Description Dr Adams + Dr Hughes - MEG UK 2018 meeting (Cardiff) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact TBC
Year(s) Of Engagement Activity 2018
URL https://meguk.ac.uk/category/events/
 
Description Dr Adams - Biofind conference (July 2017) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact TBC
Year(s) Of Engagement Activity 2017
 
Description Dr Adams - Cambridge Neuroscience Network (August 2019) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact TBC
Year(s) Of Engagement Activity 2019
 
Description Dr Adams - Computational Psychiatry course (Zurich, August 2017) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact This 5-day course is designed to provide students with the necessary toolkit to master challenges in computational psychiatry research. We want this course to be practically useful for students (Master, PhD, Postdoc) who would like to apply modeling techniques to study learning, decision-making or brain physiology in patients with psychiatric disorders. The course will teach not only the theory of computational modeling, but also demonstrate open source software in application to example data sets.
Year(s) Of Engagement Activity 2017
URL https://www.quentinhuys.com/tcpw/courses/zurich-computational-psychiatry-course-august-2017/
 
Description Dr Adams - Invited talk at UCL to at Friston Group about DCM models (October 2017) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact TBC
Year(s) Of Engagement Activity 2017
 
Description Dr Adams - attended 11th International Conference on Frontotemporal Dementia 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact TBC
Year(s) Of Engagement Activity 2018
URL http://www.dcconferences.com.au/icftd2018/
 
Description Dr Adams - attended FENS Forum 2018 (Berlin) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact The FENS Forum of Neuroscience is the largest international neuroscience meeting in Europe, involving all neuroscience societies' members of FENS, and held biannually on every even year. The FENS Forum strives to promote excellence in neuroscience research in Europe at large and to facilitate the interaction between scientists in and outside Europe. Participants in the FENS Forums are scientists at all career levels working in all areas of neuroscience research. Students and early career researchers are extensively represented as a group in the Forum.
Year(s) Of Engagement Activity 2018
URL https://www.fens.org/News-Activities/Calendar/Meetings/2018/07/FENS-Forum-2018/
 
Description Dr Frank Hezemans - Festival of Neuroscience 2021 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Presenting recent results regarding the role of the locus coeruleus in apathy in Parkinsons disease. The purpose is to generate discussion and raise awareness of the role of this brain region and in regulating cognitive deficits associated in Parkinsons disease.
Year(s) Of Engagement Activity 2021
URL https://meetings.bna.org.uk/bna2021/
 
Description Dr Frank Hezemans - Neuroscience Network Symposium, Cambridge (27th Jul '19) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Approx 100 researchers attended (viewed poster presentation) on recent results from Parkinsons disease study, focusing on mechanisms of sensory/motor integration and potential benefit of treatment by atomoxetine.
Year(s) Of Engagement Activity 2019
URL https://www.neuroscience.cam.ac.uk/events/ABC2019/pages/about-abc.html
 
Description Dr Frank Hezemans - Poster presentation at International Behavioral Neuroscience Society 2020 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Approx 100 researchers attended (viewed poster presentation) on recent results from Parkinsons disease study, focusing on mechanisms of sensory/motor integration and potential benefit of treatment by atomoxetine.
Year(s) Of Engagement Activity 2020
URL https://www.ibnsconnect.org/ibns-2020-annual-meeting
 
Description Dr Frank Hezemans - Science Night 2021 prerecorded talk aimed at the general public about Parkinson's disease and noradrenaline 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Public event discussing various research studies bering carried out at MRC Cognition and Brain Sciences unit (University of Cambridge). Dr Hezemens focuses particularly on discussing Parkinson's disease and the effects of noradrenaline on the brain.
Year(s) Of Engagement Activity 2021
URL https://www.mrc-cbu.cam.ac.uk/blog/2020/01/mrc-cbu-science-night-cambridge-science-festival-2020/
 
Description Dr K Tsvetanov poster: "Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia", Society for Neuroscience Annual Scientific Meeting, Chicago USA, (19-24 Oct '19) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Tsvetanov KA, Gazzina S, Jones PS, Rowe JB. "Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia", Society for Neuroscience Annual Scientific Meeting, Chicago, USA, 19-24 October 2019
Year(s) Of Engagement Activity 2019
 
Description Dr K Tsvetanov talk: "Cognitive predictors of healthy ageing in CamCAN", MEG Collaboration Meeting, Cambridge, (9th Sep '19) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Scheduled invited talk.
Year(s) Of Engagement Activity 2019
 
Description Dr K Tsvetanov talk: "Modelling the resilient brain: challenges and opportunities", Cambridge Neuroscience Theme Development Workshops (30th Mar '20) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Scheduled invited talk.
Year(s) Of Engagement Activity 2020
 
Description Dr K Tsvetanov, poster: "Cardiovascular and neurovascular factors are independently associated with resting BOLD signal variability". OHBM, Rome, (9-13 Jun ')19 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Tsvetanov KA, Henson RNA, Jones PS, Mutsaerts J, Tyler LK, Cam-CAN, Rowe JB. "Cardiovascular and neurovascular factors are independently associated with resting BOLD signal variability". Organization for Human Brain Mapping, Rome, Italy, 9-13 June 2019
Year(s) Of Engagement Activity 2019
 
Description Dr Kocagoncu - Cognitive frailty and Alzheimer's disease: a continuum of associative memory processing deficits. MEG UK (26th-27th March 2018). 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Kocagoncu, E., Nesbitt, D., Emery, T., Henson, R., Cam-Can, and Rowe, J. B. (26th-27th March 2018). Cognitive frailty and Alzheimer's disease: a continuum of associative memory processing deficits. MEG UK, Derry, UK.
Year(s) Of Engagement Activity 2018
 
Description Eastern AHSN Neurodegeneration, Bringing academic and business communities together to improve Dementia outcomes, Cambridge 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact a cross-sector symposium on dementia research.
Year(s) Of Engagement Activity 2019
 
Description FTD Europe Workshop, Italy 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact TBC
Year(s) Of Engagement Activity 2020
 
Description FTD KOL meeting - University of Pennsylvania 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A meeting with KOL from academia and industry with the FDA, on new science based trials designs for FTD
Year(s) Of Engagement Activity 2019
 
Description FTD carers meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Afternoon event for carers of people with FTD, updating on research, clinical practice, open Q&A and networking among carers
Year(s) Of Engagement Activity 2018
 
Description GENFI international meeting 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact two day workshop on genetic FTD, progress in research and future prospects
Year(s) Of Engagement Activity 2018
URL http://genfi.org.uk/
 
Description Genetic diagnosis of dementia 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact EAN 2018 special event and debate on genetic diagnosis of young onset dementia - making the case for expansion of genetic services available.
Matched paper published in JNNP
Year(s) Of Engagement Activity 2018
 
Description Hezemans - (16th June 2018) Experiment demonstation. MRC Festival of Medical Research - Unit open day, Cambridge, UK 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Experiment demonstration
Year(s) Of Engagement Activity 2018
 
Description Hezemans - Experiment Demonstration (14th March 2018). MRC CBU Science Night, Cambridge Science Festival 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Experiment demonstration
Year(s) Of Engagement Activity 2018
 
Description Inernational symposium on PSP/CBD 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact International symposium, including talk and posters from our group, on progress in PSP and CBD reesarch
Engagement with Pharma
Year(s) Of Engagement Activity 2018
 
Description MRC CBU Science Night - Cambridge Science Festival 2019 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Demonstrations of research studies, including VR game
Year(s) Of Engagement Activity 2019
URL http://www.mrc-cbu.cam.ac.uk/blog/2019/01/mrc-cbu-science-night-cambridge-science-festival-2019/
 
Description Nesbitt - Q A with Dr David Nesbitt. The London Brain Project. Special Edition on Beyond Memories (2017) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Nesbitt, D. (28th September 2017). Q&A with Dr David Nesbitt. The London Brain Project. Special Edition on "Beyond Memories".
Year(s) Of Engagement Activity 2017
 
Description PSP Matters 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Extended interview on PSP research, researchers, motivation and progress.
How donations lead to real research progress, and added value
Year(s) Of Engagement Activity 2018
URL https://pspassociation.org.uk/information-and-support/just-been-diagnosed/psp-matters/
 
Description PSP carers meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Special meeting to initiate a PSP support network locally, and engage families with PSP mattes, clinical and research, and the local team
Year(s) Of Engagement Activity 2018
 
Description Patient and Public Involvement - Rowe Lab, Cambridge (Dec '20) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact A small panel of carers offered to support the Rowe group with research activity within the group. To date, this has been primarily to review study documentation prior to submission for grant application/ethical review. The carers support the team in making sure that the study documentation is clear and understandable, as well as raising any concerns or questions about the proposed research. Follow up planned for February 2021 to provide feedback for an ethics application for a drug trial which is due to commence in 2021.
Year(s) Of Engagement Activity 2020
 
Description Patient and Public Involvement - Rowe Lab, Cambridge (Dec '20) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact A face to face meeting was an initiation of a standalone PPI group for FTD within the Rowe Lab. By inviting patients and their carers to December '20 meeting we looked at 1) 2 research studies and reviewed them (Dr Rittman and Dr Passamonti) 2) 1 ethical question discussed within the group. Post meeting feedback was received by participants and a suggestion made for another meeting to take part later in the 2020. In addition, research nurses are sending out questionnaires to all patients/carers attending the Disorders of Movement and Cognition Clinic (DMC) and Frontotemporal Dementia Clinic (FDC) to assist us in reviewing the clinics and identifying areas of improvement and further needs.
Year(s) Of Engagement Activity 2019
 
Description Pharma partnerships under CDA 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact A series of six pharma partnership meetings related to PSP and FTD novel therapeutics, under CDA/NDA
Scoping the needs and opportunity, reviewing candidate product preclinical data, and developing better trial design,
Year(s) Of Engagement Activity 2018
 
Description Prof J B Rowe - FTD carers meeting - Cambridge (20th Sep '20) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Rowe Group organises an annual Frontotemporal Dementia (FTD) meeting for carers of our patients to highlight their importance for our research and thank them for enabling us to see their family members in the clinic.
Year(s) Of Engagement Activity 2019
 
Description Prof J B Rowe - PSP/CBS carers annual meeting - Cambridge (10th Oct '20) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact We meet with carers of patients that come to our clinic with PSP and CBS diagnosis to keep them updated on our research and thank them for their continuing support by helping their family members to take part in our studies.
Year(s) Of Engagement Activity 2019
 
Description Prof J B Rowe Washington meeting:Key Opinion Leaders meeting with FDA and Frontotemporal dementia prevention initiative (31st Oct '19) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact 31st Oct - Washington - Key Opinion Leaders meeting with FDA and Frontotemporal dementia prevention initiative - Progranulin trials
Year(s) Of Engagement Activity 2019
 
Description Prof J B Rowe, Copenhagen University (Neurobiology Unit) "Inflammation and Tau burden in dementia: associations with phenotype and brain connectivity" (2nd Oct '19) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact 2nd October - Ciopenhagen University, Neurobiolgy Research Unit - Inflammation and Tau burden in dementia: associations with phenotype and brain connectivity.
Year(s) Of Engagement Activity 2019
 
Description Prof J B Rowe, Regional Psychiatry talk "Frontotemporal dementia challenges and progress" (5th June '19) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Eastern Division of the Royal College of Psychiatrists talk.
Year(s) Of Engagement Activity 2019
 
Description Prof J B Rowe: "Restoring brain function in dementia", Beacon workshop, University of Nottingham (12th April '19) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Restoring brain function in dementia @ Nottingham Beacon workshop Beacon workshop on sensorimotor brain oscillations #914915804 When: 12 April 2019
Year(s) Of Engagement Activity 2019
 
Description Prof J B Rowe: Academic Health Science Network Neurodegeneration meeting (5th Nov '19) "New therapeutics in dementia" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact industry forum on dementia research opportunities and networks
Year(s) Of Engagement Activity 2019
 
Description Prof J B Rowe: Danish Young Neurologists talk "Phenocopies of behavioural variant frontotemporal dementia AND Apathy and impulsivity" (18th Jan '20) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact 18th Jan 20 - Danish Young Neurologists n=150 Phenocopies of behavioural variant frontotemporal dementia
AND Apathy and impulsivity
Year(s) Of Engagement Activity 2020
 
Description Prof J B Rowe: EUFIND Bonn 7T meeting talk: "Neurochemistry of frontotemporal lobar degeneration: frontotemporal dementia and progressive supranuclear palsy" (30th Jan '20) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 30th January Bonn EUFIN meeting for 7T - Neurochemistry of frontotemporal lobar degeneration: frontotemporal dementia and progressive supranuclear palsy
Year(s) Of Engagement Activity 2020
 
Description Prof J B Rowe: FTD/ALS workshop "Clinical Outcomes and Imaging for FTD" (7th Oct '19) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact 7th Oct 2019 - FTD-ALS WORKSHOP WITH DRUG DISCOVERY FUND AND CROSS-SECTOR DEMENTIA STAKEHOLDERS - Clinical outcomes and imaging for FTD
Year(s) Of Engagement Activity 2019
 
Description Prof J B Rowe: Magdeburg/DZNE Locus Coeruleus "Noradrenergic deficit and restoration in Progressive Supranuclear Palsy" (12th Dec '19) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 12th Dec Magdeburg/DZNE LC meeting - "Noradrenergic deficit and restoration in Progressive Supranuclear Palsy
Year(s) Of Engagement Activity 2019
 
Description Prof J B Rowe: talk at ALBA Lab University of San Francisco: Frontotemporal dementia: opportunities, challenges, progress (29th Jan '20) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Jan UCSF ALBA - Frontotemporal dementia: opportunities, challenges, progress.
Year(s) Of Engagement Activity 2020
URL https://twitter.com/AlbaLanguage/status/1222334320745963522
 
Description Prof J B Rowe: talk at Copenhagen University, Bispebjerg Hospital "Progressive Supranuclear Palsy" (16th Jan '20) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact JAN 2020 - COPENHAGEN university - bispebjerg hospital - "progressive supranuclear palsy"
Year(s) Of Engagement Activity 2020
 
Description Prof J B Rowe: talk at FRONTIERS FTD Europe Workshop "From genetic and sporadic FTD to the European Epidemiological Study: possible connection (6th Feb '20) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact https://www.italianacongressi.it/articoli/allegato/13_brochure-br.pdf
Year(s) Of Engagement Activity 2020
URL https://www.italianacongressi.it/articoli/allegato/13_brochure-br.pdf
 
Description Rittmann, T. (14th May 2018). The story of a noisy brain. Pint of Science, Annual Science Festival, Castle Bar, Cambridge, UK 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Increase awareness. Discuss science with general public
Year(s) Of Engagement Activity 2018
 
Description Rowe - Brain training app found to improve memory in people with mild cognitive impairment. University of Cambridge for Science Daily (2017) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Rowe, J. B. (3rd July 2017). 'Brain training' app found to improve memory in people with mild cognitive impairment. University of Cambridge for Science Daily.
www.sciencedaily.com/releases/2017/07/170703083310.htm
Year(s) Of Engagement Activity 2017
URL http://www.sciencedaily.com/releases/2017/07/170703083310.htm
 
Description Rowe - Cambridge Science Festival 2018 - Molecules to Memory - Advances in Dementia Research, hosted by ARUK local network 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact public talk at Cambridge Science Festival
Year(s) Of Engagement Activity 2018
 
Description Rowe - Existing drugs step up in battle against neurodegenerative disease. Magazine of the PSP Association (2017) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Rowe, J. B. (9th October 2017). Existing drugs step up in battle against neurodegenerative disease. Magazine of the PSP Association.
Year(s) Of Engagement Activity 2017
 
Description Rowe - FTD Carers' Meeting, Department of Clinical Neurosciences, University of Cambridge, UK (2014) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Rowe, J. B. (24th March 2014). FTD Carers' Meeting, Department of Clinical Neurosciences, University of Cambridge, UK.
Year(s) Of Engagement Activity 2014
 
Description Rowe - FTD Carers' Meeting. Department of Clinical Neurosciences, University of Cambridge (2017). 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Rowe, J. B. (13th September 2017). FTD Carers' Meeting. Department of Clinical Neurosciences, University of Cambridge; give feedback to carers and also get feedback from them.
Year(s) Of Engagement Activity 2017
 
Description Rowe - FTD-UK Annual Meeting (2017) - Debate 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact A discussion of imaging's contribution to FTD diagnosis, prognosis and stratification
Year(s) Of Engagement Activity 2017
 
Description Rowe - First dementia patient is scanned. BRC Communications, R D Newsletter, Cambridge Biomedical Research Centre (2017) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Rowe, J. B. (6th October 2017). First dementia patient is scanned. BRC Communications, R&D Newsletter, Cambridge Biomedical Research Centre.
Year(s) Of Engagement Activity 2017
 
Description Rowe - He couldn t believe there was no cure: Husband of ski instructor, 32, struck down by rare dementia shortly after their wedding has shed so many tears since her diagnosis, her father reveals. Andrew Young for Daily Mail Online (2017) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Rowe, J. B. (4th September 2017). He couldn't believe there was no cure': Husband of ski instructor, 32, struck down by rare dementia shortly after their wedding has shed 'so many tears' since her diagnosis, her father reveals. Andrew Young for Daily Mail Online. http://www.dailymail.co.uk/news/article-4851272/Husband-couldn-t-believe-no-cure.html; mentions only James Rowe
Year(s) Of Engagement Activity 2017
URL http://www.dailymail.co.uk/news/article-4851272/Husband-couldn-t-believe-no-cure.html
 
Description Rowe - Meeting the Scientist. Cambridge Science Festival, Cambridge, UK (25th March 2018) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Increase public awareness for rare dementia types (PSP, SD, frontotemporal dementia).
Year(s) Of Engagement Activity 2018
 
Description Rowe - Misplace in Space (2016-2017) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Rowe, J. B. (1st-6th September 2017). Misplaced in Space. Emily Fisher, Work by MA students shown in the MA Degree Show 2017 with work related to individual's experience to live with dementia. Norwich University of the Arts, UK. http://www.nua.ac.uk/ma-degree-show-catalogue-2017/emily-fisher/; An interactive exhibition about living with Dementia,
Year(s) Of Engagement Activity 2017
URL http://www.nua.ac.uk/ma-degree-show-catalogue-2017/emily-fisher/
 
Description Rowe - NIMROD study. BRC Communications, R D Newsletter, Cambridge Biomedical Research Centre (2017) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Rowe, J. B. (6th October 2017). NIMROD study. BRC Communications, R&D Newsletter, Cambridge Biomedical Research Centre.
Year(s) Of Engagement Activity 2017
 
Description Rowe - Norwegian TV - Modafinil test by programme leader Emma Claire (2017) 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact On cognitive enhancement
Year(s) Of Engagement Activity 2017
 
Description Rowe - She used to light up a room - but now 'beautiful' Becky from Suffolk finds it hard to speak after crushing dementia diagnosis. Emily Townsend for East Anglian Daily Times (2017) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Rowe, J. B. (11th September 2017). She used to light up a room - but now 'beautiful' Becky from Suffolk finds it hard to speak after crushing dementia diagnosis. Emily Townsend for East Anglian Daily Times. http://www.eadt.co.uk/news/she-used-to-light-up-a-room-but-now-beautiful-becky-from-suffolk-finds-it-hard-to-speak-after-crushing-dementia-diagnosis-1-5189016; mentions James Rowe
Year(s) Of Engagement Activity 2017
URL http://www.eadt.co.uk/news/she-used-to-light-up-a-room-but-now-beautiful-becky-from-suffolk-finds-it...
 
Description Rowe, 'Brain training' app found to improve memory in people with mild cognitive impairment. Cambridge Neuroscience News, UK (2017) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Rowe, J. B. (18th July 2017). 'Brain training' app found to improve memory in people with mild cognitive impairment. Cambridge Neuroscience News, UK.
http://www.neuroscience.cam.ac.uk/news/article.php?permalink=349646f424
Year(s) Of Engagement Activity 2017
URL http://www.neuroscience.cam.ac.uk/news/article.php?permalink=349646f424
 
Description Rowe, J. B. (28th September 2017) Understanding frontotemporal dementia: an interview with Professor James Rowe - Interview for the National Institute for Health Research (NIHR) (2017) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Rowe, J. B. (28th September 2017) Understanding frontotemporal dementia: an interview with Professor James Rowe. Interview for the National Institute for Health Research (NIHR). https://www.nihr.ac.uk/news-and-events/features/behind-the-research/Understanding-frontotemporal-dementia.htm
Year(s) Of Engagement Activity 2017
URL http://www.nihr.ac.uk/news-and-events/features/behind-the-research/Understanding-frontotemporal-deme...
 
Description Rowe: FTD carers meeting (2017) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Research discussion to regional carers
Year(s) Of Engagement Activity 2017
 
Description Seven lab members (22nd March 2018). 5k for the PSP Association to raise money to support people affected by CBD & PSP, Cambridge, UK. 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Run for PSP and CBD to increase awareness. https://www.pspassociation.org.uk/fundraising/5kforpspa/; promoted on twitter
Year(s) Of Engagement Activity 2018
 
Description Synaptic Health Symposium 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact A one-day workshop, and shorter follow up meetings, to engage academic and industry partners in Synaptic Health Research
Year(s) Of Engagement Activity 2018
URL https://www.dementiasplatform.uk/for-researchers/expert-communities-1/synaptic-health-community
 
Description Tomassinie - Experiment Demonstration (14th March 2018). MRC CBU Science Night, Cambridge Science Festival, Cambridge, UK 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Experiment demonstation
Year(s) Of Engagement Activity 2018
 
Description UK Network of Open Research Working Groups (UK-ORWG) - Sep 2020 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Open Research Working Groups (ORWGs) are action-oriented teams within higher education that are seeking to reform science to make the processes and products of research as transparent, accessible and reproducible as possible.

You can read more about ORWGs in our primer, prepared for the UK Reproducibility Network, or hear about the UK-ORWG in this podcast.

The UK Network of ORWGs brings these groups together under one umbrella to focus and amplify our shared mission. We are working to develop policy initiatives, host events and conferences, produce educational materials and workshops, conduct collaborative research projects centered on open science, and assess community needs to bring more researchers toward open practices.

Membership is open to any ORWG located within the UK higher education sector, and we also welcome international affiliates. Key individuals may also be invited to join. If you would like to join the group as contributor, please contact Chris Chambers or Charlotte Hartwright, or request access through the OSF.
Year(s) Of Engagement Activity 2020
URL https://osf.io/vgt3x/wiki/home/
 
Description Vazquez - PSPA-funded researchers present at international conference. Magazine of the PSP Association (2017) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Vazquez Rodriguez, P. (9th October 2017). PSPA-funded researchers present at international conference. Magazine of the PSP Association.
Year(s) Of Engagement Activity 2017
 
Description Vazquez/Rowe - Fighting PSP both in and outside the lab. PSP Association Magazine (2017) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Vazquez Rodriguez, P. (September 2017). Fighting PSP both in and outside the lab. PSP Association Magazine; raise awareness for PSP
Year(s) Of Engagement Activity 2017